Talquetamab (tal) plus daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.

被引：0

作者：

Dholaria, Bhagirathbhai R.

Weisel, Katja

Mateos, Maria-Victoria

Goldschmidt, Hartmut

Martin, Thomas G.

Morillo, Daniel

Reece, Donna Ellen

Rodriguez-Otero, Paula

Bhutani, Manisha

D'Souza, Anita

Oriol, Albert

Rosinol, Laura

Bahlis, Nizar J.

Bakshi, Kalpana

Kang, Lijuan

Vandenberk, Lien

Smit, Marie-Anne Damiette

Wasch, Ralph

van de Donk, Niels W. C. J.

Chari, Ajai

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[3] Univ Hosp Salamanca, Salamanca, Spain

[4] Univ Klinikum Heidelberg, Med Klin 5, Heidelberg, Germany

[5] Natl Ctr Tumorerkrankungen, Heidelberg, Germany

[6] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco Med Ctr, San Francisco, CA USA

[7] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain

[8] Princess Margaret Canc Ctr, Toronto, ON, Canada

[9] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[10] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[11] Med Coll Wisconsin, Milwaukee, WI USA

[12] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain

[13] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain

[14] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[15] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[16] Janssen Res & Dev, Spring House, PA USA

[17] Janssen Res & Dev, Antwerp, Belgium

[18] Janssen Biol Europe, Leiden, Netherlands

[19] Freiburg Univ, Med Ctr, Freiburg, Germany

[20] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands

[21] Mt Sinai Sch Med, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8003

引用

下载

页数：1

共 50 条

[1] Talquetamab plus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results
Dholaria, Bhagirathbhai
Weisel, Katja
Mateos, Maria-Victoria
Goldschmidt, Harmut
Martin, Thomas
Morillo, Daniel
Reece, Donna
Rodriguez-Otero, Paula
Bhutani, Manisha
D'Souza, Anita
Oriol, Albert
Rosinol, Laura
Bahlis, Nizar
Bakshi, Kalpana
Kang, Lijuan
Vandenberk, Lien
Smit, M. Damiette
Wasch, Ralph
van de Donk, Niels
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S476 - S477
[2] Durvalumab (DURVA) plus daratumumab (DARA) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).
Richardson, Paul G.
Bensinger, William
Weisel, Katja C.
Boyd, Kevin
Ramasamy, Karthik
Gonzalez, Esther
Favre-Kontula, Linda
Peluso, Teresa
Sternas, Lars Axel
Di Casoli, Carl
Zaki, Mohamed H.
Facon, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[3] Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)
Richardson, Paul G.
Oriol, Albert
Larocca, Alessandra
Rodriguez Otero, Paula
Moreb, Jan
Blade, Joan
Hassoun, Hani
Cavo, Michele
Alegre, Adrian
Mazumder, Amitabha
Maisel, Christopher
Paner, Agne
Leleu, Xavier
Zonder, Jeffrey A.
Harmenberg, Johan
Thuresson, Sara
Zubair, Hanan
Mateos, Maria-Victoria
CANCER RESEARCH, 2019, 79 (13)
[4] Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104)
Pour, Ludek
Efebera, Yvonne
Granell, Miquel
Hajek, Roman
Oriol, Albert
Delaunay, Jacques
Le Du, Katell
Eveillard, Jean-Richard
Karlin, Lionel
Maisnar, Vladimir
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Moreb, Jan
Ribrag, Vincent
Richardson, Paul G.
Straub, Jan
Byrne, Catriona
Jacques, Christian
Zubair, Hanan
Ocio, Enrique
CANCER RESEARCH, 2019, 79 (13)
[5] Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
Chari, Ajai
Hari, Parameswaran
Bahlis, Nizar J.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Dholaria, Bhagirathbhai
Garfall, Alfred L.
Goldschmidt, Hartmut
Kortuem, K. Martin
Krishnan, Amrita Y.
Martin, Thomas
Morillo Gilles, Daniel
Oriol, Albert
Reece, Donna E.
Rodriguez, Cesar
Rodriguez-Otero, Paula
San-Miguel, Jesus F.
Usmani, Saad Z.
Verona, Raluca I.
Lin, Shun Xin Wang
Prior, Thomas J.
Wade, Mark
Weiss, Brendan M.
Goldberg, Jenna D.
Askari, Elham
BLOOD, 2021, 138
[6] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Knop, Stefan
Lonial, Sagar
Richardson, Paul
Popat, Rakesh
Stadtmauer, Edward A.
Larsen, Jeremy T.
Oriol, Albert
Jagannath, Sundar
Cook, Gordon
Badros, Ashraf Z.
Rodriguez-Otero, Paula
Siegel, David
Nguyen, Tuong Vi
Di Micco, Antonia
Amin, Alpesh
Chen, Min
Kueenburg, Elisabeth
Van De Donk, Niels W. C. J.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 171 - 171
[7] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Lonial, Sagar
Richardson, Paul G.
Popat, Rakesh
Stadtmauer, Edward A.
Larsen, Jeremy T.
Oriol, A.
Knop, Stefan
Jagannath, Sundar
Cook, Gordon
Badros, Ashraf Z.
Rodriguez-Otero, Paula
Siegel, David S.
Nguyen, Tuong Vi
Di Micco, Antonia
Amin, Alpesh
Chen, Min
Kueenburg, Elisabeth
van de Donk, Niels W. C. J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S9 - S9
[8] Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.
Rodriguez-Otero, Paula
Schinke, Carolina D.
Chari, Ajai
Lipe, Brea
Lavi, Noa
Rasche, Leo
Vishwamitra, Deeksha
Skerget, Sheri
Verona, Raluca
Ma, Xuewen
Khedkar, Sheetal
Hilder, Brandi
Masterson, Tara J.
Campagna, Michela
Renaud, Thomas
Tolbert, Jaszianne A.
Heuck, Christoph
Smit, Marie-Anne Damiette
van de Donk, Niels W. C. J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[9] Analysis of Infections and Parameters of Humoral Immunity in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Talquetamab (tal) Monotherapy in MonumenTAL-1
Rodriguez-Otero, Paula
Schinke, Carolina
Chari, Ajai
Lipe, Brea
Lavi, Noa
Rasche, Leo
Vishwamitra, Deeksha
Skerget, Sheri
Verona, Raluca
Ma, Xuewen
Khedkar, Sheetal
Hilder, Brandi
Masterson, Tara
Campagna, Michela
Renaud, Thomas
Tolbert, Jaszianne
Heuck, Christoph
Smit, M. Damiette
van de Donk, Niels
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S480 - S480
[10] Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial
Richardson, Paul G.
Sandhu, Irwindeep
Hofmeister, Craig C.
Orlowski, Robert Z.
White, Darrell
Belotti, Angelo
Hansen, Charlotte Toftmann
Raje, Noopur S.
Chow, Tracy T.
Zhou, Zehua
Civardi, Tiziana
Koo, Phillip
Zhu, Yue
Katz, Jessica
Oriol, Albert
BLOOD, 2023, 142

← 1 2 3 4 5 →